[The olfactor-genital syndrome (author's transl)].
1. Only FSH was increased after intravenous administration of 0.025 mg of GnRH in 2 female patients suffering from olfacto-genital syndrome. LH-serum-concentrations increased significantly, only when 0.1 mg GnRH was applicated intravenously twice with an interval of one hour.2. The response of hPRL-secretion to 0.2 mg TRH was found normal in both patients. However, when 25 mg chlorpromacine were administered intramuscularly, only one patient responded with an adequate rise of serum-hPRL. 3. One patient became pregnant during treatment with HMG/HCG. The clinical course of pregnancy was quite normal. HPL- and HCG-levels were in the normal, hPRL in the low normal range during pregnancy.
D000328:Adult; D000568:Amenorrhea / Q000150:complications* / Q000188:drug therapy; D002746:Chlorpromazine; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000627:therapeutic use; D000857:Olfaction Disorders / Q000150:complications* / Q000188:drug therapy; D010906:Pituitary Hormone-Releasing Hormones; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D013577:Syndrome; D013973:Thyrotropin-Releasing Hormone
D006063:Chorionic Gonadotropin; D010906:Pituitary Hormone-Releasing Hormones; D013973:Thyrotropin-Releasing Hormone; D008596:Menotropins; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002746:Chlorpromazine
Das olfacto-genitale Syndrom.